Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Emily G Hoffman und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prediabetic State, Hypoglycemia, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Glycomics Network, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Aims
To examine if glucagon counterregulatory defects exist in a rat model of prediabetes (pre‐T2D) and to assess if a selective somatostatin receptor 2 antagonist (SSTR2a), ZT‐01, enhances the glucagon response to insulin‐induced hypoglycaemia. Materials and methods Hyperglycaemia was induced in 8‐ to 9‐week‐old male, Sprague‐Dawley rats via 7 weeks of high‐fat diet followed by a single, low‐dose intraperitoneal injection of streptozotocin (30 mg/kg). After 2 weeks of basal insulin therapy (0‐4 U/d insulin glargine, administered subcutaneously [SC]) to facilitate partial glycaemic recovery and a pre‐T2D phenotype, n = 17 pre‐T2D and n = 10 normal chow‐fed control rats underwent the first of two hypoglycaemic treatment‐crossover experiments, separated by a 1‐week washout period. On each experimental day, SSTR2a (3 mg/kg ZT‐01, SC) or vehicle was administered 1 hour prior to insulin‐induced hypoglycaemia (insulin aspart, 6 U/kg, SC).
Results
Glucagon counterregulation was marginally reduced with the induction of pre‐T2D. Treatment with SSTR2a raised peak plasma glucagon levels and glucagon area under the curve before and after insulin overdose in both and pre‐T2D rats. Blood glucose concentration was elevated by 30 minutes after SSTR2a treatment in pre‐T2D rats, and hypoglycaemia onset (≤3.9 mmol/L) was delayed by 15 ± 12 minutes compared with vehicle ( P < 0.001), despite similar glucose nadirs in the two treatment groups (1.4 ± 0.3 mmol/L). SSTR2a treatment had no effect on blood glucose levels in the control group or on the hypoglycaemia‐induced decline in plasma C‐peptide levels in either group.
Conclusions
Treatment with an SSTR2a increases glucagon responsiveness and delays the onset of insulin‐induced hypoglycaemia in this rat model of pre‐T2D where only a modest deficiency in glucagon counterregulation exists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
- Zucara Therapeutics, Vancouver, British Columbia, Canada.
ORCID-Profile: Emily G Hoffman, Michael C Riddell
Förderung
- Canadian Glycomics Network
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Hoffman, E. G., D'Souza, N. C., Aiken, J., Atherley, S., Liggins, R., & Riddell, M. C. (2023). Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15002
Vancouver
Hoffman EG, D'Souza NC, Aiken J, Atherley S, Liggins R, Riddell MC. Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15002
BibTeX
@article{Hoffman2023,
author = {Hoffman, Emily G and D'Souza, Ninoschka C and Aiken, Julian and Atherley, Sara and Liggins, Richard and Riddell, Michael C},
title = {Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15002}
}
EUVIMED